# Clarus Therapeutics

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/clarus-therapeutics

- Industry: Biotechnology
- Headquarters: Northbrook, US
- Website: www.clarustherapeutics.com
- Total disclosed funding: $8M
- Latest round: Series C (Nov 27, 2007)
- Investors on record: 2

## About

Clarus Therapeutics is a healthcare company focused on developing innovative hormone therapies, particularly for addressing testosterone deficiency in men, thereby enhancing their overall well-being.Founded in 2003 and headquartered in Northbrook, US, Clarus Therapeutics specializes in hormone therapy, particularly oral testosterone replacement therapy. The company has secured a total of USD 30.00 mn through funding rounds, including a Private Placement/Follow on round on April 27, 2022. Bob Dudley serves as the CEO. The company has executed a total of 8 deals, with the most recent occurring in April 2022.Clarus Therapeutics specializes in delivering innovative therapeutic solutions to address various health challenges, with a particular focus on hormone therapy. Their flagship product, an oral testosterone replacement therapy, is designed to treat men with testosterone deficiency, enhancing their quality of life by alleviating symptoms associated with low testosterone levels, such as fatigue, reduced libido, and mood disturbances. The company aims to improve patient adherence through its convenient oral dosing, providing an alternative to traditional injectable therapies. Clarus Therapeutics primarily serves a client base that includes healthcare providers, endocrinologists, and urologists, as well as pharmacies that dispense their products. Geographically, the company’s products are available in the United States, targeting a diverse population that includes adult men diagnosed with hypogonadism.Clarus Therapeutics generates revenue through direct sales of its oral testosterone therapy to healthcare providers and patients. The company employs a B2B transaction structure, where pharmacies purchase the product in bulk, subsequently offering it to end consumers. The pricing strategy for their flagship product is set to reflect its value in addressing testosterone deficiency, with structured payments based on negotiated terms with healthcare providers and pharmacies. Through these partnerships, Clarus Therapeutics is able to reach a wide audience of patients and healthcare professionals, positioning itself as a critical player in the hormone therapy market. The revenue model is designed to ensure a streamlined process from product development to patient access, fostering a sustainable business growth trajectory.In April 2022, Clarus Therapeutics raised USD 30.00 mn to support growth initiatives for its product, JATENZO, which includes direct-to-consumer advertising and expansion of its R&D pipeline. The company aims to develop and launch new products to further its offerings in hormone therapy. Additionally, there are plans to expand into new markets, although specific regions have not been disclosed. The funding will drive these initiatives, enhancing Clarus's presence in the therapeutics sector.

## Funding rounds

- Series C, Nov 27, 2007, $8M — Thomas, McNerney & Partners, H.I.G. BioHealth Partners
- Series A, Feb 1, 2004 — Thomas, McNerney & Partners

## Investors

- Thomas, McNerney & Partners (https://capitalatlas.ai/funds/thomas-mcnerney-partners) — Series A, Series C
- H.I.G. BioHealth Partners (https://capitalatlas.ai/funds/h-i-g-biohealth-partners) — Series C